Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
| Status: | Archived |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | April 2011 |
| End Date: | April 2012 |
A Phase 1 Study in Patients With Type 1 Diabetes Mellitus to Evaluate the Single and Multiple Dose Pharmacokinetics and Safety of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration
The purpose of this study is to assess safety and tolerability and determine the
pharmacokinetics of single and multiple (4-5) dose subcutaneous administration of CBX129801
(long-acting synthetic C-peptide) in type 1 diabetes patients.
This study has four parts (A-D). Part is A is open label to test an estimated equivalent of
"replacement" dose of C-peptide. Parts B-D will utilize a randomized placebo-controlled
double-blind design.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials